XML 117 R60.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Investments accounted for using the equity method (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Interests In Other Entities [Abstract] |
Summary of Investments in Associates and Joint Ventures |
(€ million) | % interest | 2024 | 2023 | 2022
EUROAPI(a) | 29.6 | 82 | 162 | 392
Infraserv GmbH & Co. Höchst KG(b) | 31.2 | 102 | 90 | 97
MSP Vaccine Company(c) | 50.0 | 81 | 96 | 104
Other investments | — | 51 | 76 | 84
Total |  | 316 | 424 | 677
(a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.88 as of December 31, 2024, and €5.73 as of December 31, 2023). (b)Joint venture. (c)Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.
Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures | The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material):
| 2024 | 2023 | 2022
(€ million) | Joint ventures | Associates | Joint ventures | Associates | Joint ventures | Associates
Share of profit/(loss) from investments accounted for using the equity method(a) | 134 | (74) | 101 | (237) | 73 | (18)
Share of other comprehensive income from investments accounted for using the equity method | 3 | (5) | (7) | 7 | (3) | (1)
Total | 137 | (79) | 94 | (230) | 70 | (19)
(a)The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.88 as of December 31, 2024, and €5.73 as of December 31, 2023).
Summary of Principal Transactions and Balances with Related Parties | The principal transactions and balances with related parties are summarized below:
(€ million) | 2024 | 2023 | 2022(a)
Sales(d) | 103 | 157 | 131
Royalties and other income(d) | 71 | 14 | 21
Accounts receivable and other receivables(b) | 184 | 249 | 330
Other assets(c) | 189 | — | —
Purchases and other expenses (including research expenses)(d) | 600 | 573 | 472
Accounts payable and other liabilities | 160 | 190 | 258
(a)In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.1.). (b)Includes loans to joint ventures and associates. (c)In October 2024, Sanofi raised its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bon d. The fair value of this investment as of December 31, 2024 is €189 million. (d)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2023-01-01 -Paragraph 18 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of investments in associates and joint ventures explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of profit or loss and other comprehensive income of associates and joint ventures. + References No definition available. + Details
Name: | sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | sny_InterestsInOtherEntitiesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration